SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.3215

Change

-0.03 (-8.14)%

Market Cap

N/A

Volume

1.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-1.75 (-2.30%)

USD 228.18B
AMGN Amgen Inc

-8.47 (-2.59%)

USD 162.78B
SNY Sanofi ADR

-0.61 (-1.03%)

USD 148.55B
GILD Gilead Sciences Inc

-2.78 (-2.37%)

USD 142.46B
BIIB Biogen Inc

-7.05 (-4.68%)

USD 20.57B
GRFS Grifols SA ADR

-0.07 (-0.90%)

USD 7.13B
AMRN Amarin Corporation PLC

+0.01 (+1.12%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

N/A

USD 0.02B
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.60% 20% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.60% 20% F 23% F
Trailing 12 Months  
Capital Gain -75.64% 10% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.64% 10% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -39.22% 10% F 3% F
Dividend Return -39.22% 10% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.30% 30% F 52% F
Risk Adjusted Return -108.06% 10% F 3% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector